FALCO HOLDINGS Co.,Ltd.【JP:4671】Stock Price

Falco Holdings operates three main business segments: clinical laboratory testing, pharmacy services, and ICT (information and communications technology). Each segment is managed by dedicated subsidiaries that provide specialized services.

In clinical laboratory testing, Falco BioSystems serves as the core company, outsourcing clinical specimen testing from hospitals and clinics. The company also manufactures and sells in vitro diagnostic products and sells medical information systems. Additionally, Attest handles wholesale distribution of in vitro diagnostic products.

The pharmacy services segment is operated by Falco Pharmacies and Tulip Pharmacy. These subsidiaries operate community-based pharmacies that provide medication dispensing and health consultation services to patients.

In the ICT segment, MediSurge develops and sells medical information systems, including electronic medical records. This business supports operational efficiency at medical institutions and contributes to improved quality of healthcare.

Falco Holdings is committed to providing infrastructure that supports health and aims to support people's health and well-being through innovation. As Japan's healthy life expectancy increases and the medical and healthcare business sectors expand, the company leverages expertise and ICT capabilities developed through its clinical laboratory testing and pharmacy dispensing businesses to provide medical and healthcare support services tailored to customer needs.

The company has established a long-term vision through 2030 called "FALCO VISION 2030," aiming to transition to a sustainable and profitable revenue structure through business transformation. To realize this vision, the company is implementing a medium-term management plan for the three-year period from fiscal 2024 to 2026, designated as "FALCO INNOVATION 2026." This includes strengthening growth businesses and executing appropriate capital allocation.

Under "FALCO INNOVATION 2026," the company is advancing transformation in its clinical laboratory testing and pharmacy dispensing businesses while driving growth in its genome and ICT businesses. The company is also pursuing improved corporate value through sustainability initiatives and enhanced shareholder returns. In particular, the company has set medium-term targets for ROE improvement and operating profit growth to pursue sustainable expansion.

In the first year of implementation, the clinical laboratory testing business achieved greater efficiency, while the genome business expanded its market presence. The pharmacy dispensing business established a business model for elderly care facilities, and the ICT business made progress in developing new features. Through these initiatives, the company is progressing steadily toward achieving its medium-term management targets.